1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  05/27 04:08:54 am EDT
12.40 HKD   +9.93%
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application
CI
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

12/08/2021 | 04:48am EDT

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences share repurchases on December 8, 2021, under the program mandated by the shareholders in the Annual General Meeting and First Class Meeting of H shareholders and and the 2021 first class meeting of holders of unlisted foreign shares held on May 21, 2021. As per the mandate, the company is authorized to repurchase up to 43,170,744 class H shares, representing 10% of its issued class H share capital and 9.79% of its total issued share capital.. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with its memorandum of association and Bye-laws and the applicable laws and regulations of PRC. The authority shall expire at the earliest of the next Annual General Meeting or the revocation or variation of the mandate under the resolution by a special resolution at the next general meeting of the Company. As of May 21, 2021, the company had 441,011,443 ordinary shares (including 431,707,449 H Shares and 9,303,994 Unlisted Foreign Shares) shares in issue. On December 6, 2021, the company announced a share repurchase program. Under the program, the company will repurchase up to HKD 250 million worth of class H shares. The repurchased H Shares shall be cancelled. The Company intends to finance the repurchase by its own financial resources other than proceeds from the listing of the H Shares on the Main Board of The Stock Exchange of Hong Kong Limited in December 2019, and the placings of the H Shares in September 2020 and January 2021 respectively. The implementation period for the program is until the expiration of the authorization period of the AGM.


© S&P Capital IQ 2021
All news about VENUS MEDTECH (HANGZHOU) INC.
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
04/12Venus Medtech Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Comple..
CI
04/12Venus Medtech Wins Approval to Sell Cardiovascular Device in Europe
MT
03/31VENUS MEDTECH ANNOUNCES 2021 ANNUAL : pacesetter in China and breakthrough-maker worldwid..
AQ
03/31Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/21Atom Semiconductor announced that it has received $15.8 million in funding from Gobi Pa..
CI
03/18Venus Medtech Inc. Appoints Shakeel Osman as Senior Vice President of Sales Europe
CI
03/18Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercializ..
AQ
03/02Venus Medtech to Build Israel Center for New Heart Valve Technologies Development; Shar..
MT
03/01Venus Medtech Inc. Announces Establish of Venus Global Heart Valve Innovation Center
CI
More news
Financials
Sales 2022 661 M 98,6 M 98,6 M
Net income 2022 -312 M -46,5 M -46,5 M
Net cash 2022 2 508 M 374 M 374 M
P/E ratio 2022 -14,8x
Yield 2022 -
Capitalization 4 634 M 692 M 692 M
EV / Sales 2022 3,22x
EV / Sales 2023 2,37x
Nbr of Employees 905
Free-Float 79,7%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,58 CNY
Average target price 20,47 CNY
Spread / Average Target 93,4%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Haiyue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VENUS MEDTECH (HANGZHOU) INC.-58.11%692
STRYKER CORPORATION-11.56%89 433
SMITH & NEPHEW PLC0.19%14 238
INSPIRE MEDICAL SYSTEMS, INC.-20.06%5 075
AXONICS, INC.-6.55%2 463
DOUBLE MEDICAL TECHNOLOGY INC.-34.22%2 073